Prevalence of Dissociative Disorders in Children

January 31, 2014 updated by: Centre Hospitalier Universitaire de Nice

Prevalence of Dissociative Disorders in Children in a Population Supported in the Medico-social and Health Structures in Provence Alpes Cote d'Azur

Schizophrenia beginning before 18 years is a clinical entity not well known because of its low incidence and difficulties in the clinical diagnosis.

However, in the investigators clinical practice, due to the specialization of the investigators service, the investigators are led to hospital to receive important feel active of patients meeting the Diagnostic and Statistical Manual of Mental Disorders IV text revision (DSM IV-TR) precose schizophrenia.

The work of us team on the theme of the relationship between Pervasive Developmental Disorders and precose Schizophrenia led us to hypothesize that a number of children in care in the medical and educational institutes, hospitals and day shelters therapeutic part-time symptoms of schizophrenia or a line real early diagnosis of schizophrenia undervalued or not diagnosed.

The main goal is to estimate the prevalence of dissociative disorders in a population of children in care institutions and medical education in child psychiatry in hospitals and others structures.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

301

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Antibes, France, 06600
        • Psychiatrie infanto-juvénile - Centre Hospitalier d'Antibes
      • Fréjus, France, 83608
        • Psychiatrie infanto-juvénile-Pôle femme-mère -enfant
      • Marseille, France, 13009
        • Service de psychiatrie de l'enfant et de l'adolescent
      • Nice, France, 06000
        • Service de psychiatrie de l'enfant et de l'adolescent

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 years to 14 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 7 to 18 years
  • Supported in the partner institutions of the study
  • IQ>35 on the certificate of orientation of the Maison Départementale des Personnes Handicapées (MDPH)
  • Obtaining the agreement of parents and children

Exclusion Criteria:

  • QI<35 on the certificate file Guidance MDPH
  • Children not speaking french

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Children with Dissociative Disorders
Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
Kiddie-Schedule for Affective Disorders and Schizophrenia
children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of children diagnosed with dissociative disorders
Time Frame: between 2 and 4 hours depending children
Rate of children diagnosed with dissociative disorders: children positive for the test Kiddie-Schedule for Affective Disorders and Schizophrenia (Kiddie-SADS).
between 2 and 4 hours depending children

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of children positive for test: Autism Diagnostic Interview-Revise (ADI-R).
Time Frame: 1 day on average
1 day on average
Scores of three dimensions of schizophrenia in the Positive And Negative Syndrome Scale (PANSS)
Time Frame: 4 hours
3 dimensions: positive symptoms, negative symptoms and general psychopathology, based on these scores the diagnostic subtype of schizophrenia is established.
4 hours
Score at the Test Lillois de Communication (TLC)
Time Frame: 30 minutes
30 minutes
Score on the Wechsler Intelligence Scale for Children-Fourth Edition (WISC IV)subtests and overall intelligence quotient (IQ).
Time Frame: 4 hours
4 hours
Response time to test verbal fluency, scores on the Trail Making Test A (TMT) and TMT B.
Time Frame: 30 minutes
30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Florence ASKENAZY, PU-PH, University Hospital of Nice
  • Principal Investigator: Emmanuelle DOR, PH, University Hospital of Nice
  • Principal Investigator: François POINSO, PU-PH, AP-HM
  • Principal Investigator: Michèle BATTISTA, PH, Frejus's hospital
  • Principal Investigator: Michel BOUBLIL, PH, Antibes's hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Actual)

May 1, 2013

Study Completion (Actual)

May 1, 2013

Study Registration Dates

First Submitted

December 13, 2011

First Submitted That Met QC Criteria

January 18, 2012

First Posted (Estimate)

January 19, 2012

Study Record Updates

Last Update Posted (Estimate)

February 3, 2014

Last Update Submitted That Met QC Criteria

January 31, 2014

Last Verified

January 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Primary stage

Subscribe